Corient Private Wealth LLC Has $4.16 Million Stake in Insulet Corporation $PODD

Corient Private Wealth LLC raised its stake in Insulet Corporation (NASDAQ:PODD) by 35.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 14,595 shares of the medical instruments supplier’s stock after purchasing an additional 3,782 shares during the quarter. Corient Private Wealth LLC’s holdings in Insulet were worth $4,160,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of PODD. State Street Corp grew its stake in shares of Insulet by 2.1% in the 4th quarter. State Street Corp now owns 3,155,489 shares of the medical instruments supplier’s stock worth $896,916,000 after acquiring an additional 65,317 shares in the last quarter. Geode Capital Management LLC grew its position in Insulet by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock worth $568,274,000 after purchasing an additional 41,019 shares in the last quarter. Invesco Ltd. grew its position in Insulet by 10.5% in the 4th quarter. Invesco Ltd. now owns 1,480,562 shares of the medical instruments supplier’s stock worth $420,835,000 after purchasing an additional 141,167 shares in the last quarter. Norges Bank purchased a new stake in Insulet in the 4th quarter valued at about $300,794,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Insulet by 3.8% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 806,119 shares of the medical instruments supplier’s stock valued at $229,131,000 after buying an additional 29,690 shares during the last quarter.

Insider Transactions at Insulet

In related news, Director Timothy C. Stonesifer purchased 2,790 shares of the firm’s stock in a transaction dated Wednesday, June 3rd. The shares were purchased at an average price of $143.51 per share, with a total value of $400,392.90. Following the acquisition, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This represents a 44.63% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.36% of the stock is currently owned by insiders.

Insulet Stock Up 2.9%

PODD opened at $158.25 on Friday. The firm has a market capitalization of $10.96 billion, a P/E ratio of 36.80, a price-to-earnings-growth ratio of 1.07 and a beta of 1.13. Insulet Corporation has a one year low of $138.79 and a one year high of $354.88. The company has a fifty day moving average price of $159.09 and a 200-day moving average price of $220.64. The company has a debt-to-equity ratio of 0.71, a current ratio of 2.49 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last issued its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company had revenue of $761.70 million for the quarter, compared to the consensus estimate of $729.89 million. During the same quarter last year, the business posted $1.02 earnings per share. The firm’s revenue was up 33.9% compared to the same quarter last year. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts expect that Insulet Corporation will post 6.46 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on PODD shares. Jefferies Financial Group cut their target price on Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $205.00 price target on shares of Insulet in a research report on Wednesday, May 27th. Citigroup dropped their price target on Insulet from $175.00 to $165.00 and set a “neutral” rating on the stock in a report on Thursday, May 28th. Bank of America cut their price objective on Insulet from $288.00 to $208.00 and set a “buy” rating on the stock in a research report on Monday, May 18th. Finally, Robert W. Baird reduced their price objective on Insulet from $360.00 to $248.00 in a research note on Thursday, May 7th. Twenty-two analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Insulet presently has a consensus rating of “Moderate Buy” and a consensus price target of $238.67.

About Insulet

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.